ERBB2 and ovarian carcinoma: More importantly, in a phase II clinical trial (NCT00189579), 41 patients with HER2-overexpressing ovarian cancer who were treated with paclitaxel and carboplatin alone or in combination with trastuzumab showed modest activity, with an objective response rate of 7.3% [47].